Serplulimab reached a new record for OS in first‐line therapy of ES‐SCLC, with a two‐year OS rate that exceeded that of the chemotherapy arm by a factor of five, making it the first PD‐1 monoclonal antibody to generate good results in ES‐SCLC. Here, PDCD1 is linked to small cell lung carcinoma.